Get the Stockscreener App
26.59
6.32%
1.58
After Hours:
28.00
1.41
+5.30%
Parabilis Medicines Inc stock is traded at $26.59, with a volume of 3.38M.
It is up +6.32% in the last 24 hours and up +0.00% over the past month.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
See More
Previous Close:
$25.01
Open:
$25.26
24h Volume:
3.38M
Relative Volume:
56.97
Market Cap:
$3.25B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$24.91
$26.72
1-Week Range:
$24.51
$34.47
52-Week Range:
$24.51
$34.47
Parabilis Medicines Inc Stock (PBLS) Company Profile
Name
Parabilis Medicines Inc
Sector
Industry
Phone
-
Address
-
Compare PBLS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBLS
Parabilis Medicines Inc
|
26.59 | 3.06B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Parabilis Medicines Inc Stock (PBLS) Latest News
PBLS | Parabilis Medicines, Inc. Common Insider Trading - Quiver Quantitative
symbol__ Stock Quote Price and Forecast - CNN
RA Capital funds lift Parabilis Medicines (PBLS) common equity exposure - Stock Titan
Parabilis Medicines (PBLS) director converts preferred stock into common around IPO - Stock Titan
Parabilis (PBLS) director-linked LLC makes open-market buy of 12,500 shares - Stock Titan
Parabilis Medicines (PBLS) director converts Series F preferred into common in IPO - Stock Titan
Parabilis Medicines (PBLS) Stock Valuation After Recent 10% Single Day Decline - Yahoo Finance
Regeneron-backed Parabilis surges after record-setting IPO - MSN
Parabilis Medicines (PBLS) Stock Chart and Price History 2026 - MarketBeat
PBLS News Today | Why did Parabilis Medicines stock drop today? - MarketBeat
Parabilis Medicines prices upsized IPO at $19 per share - MSN
Parabilis Medicines prices upsized IPO at $20 per share - MSN
Current ratio of Parabilis Medicines, Inc. – NASDAQ:PBLS - TradingView
Parabilis Medicines (PBLS) Stock Price, News & Analysis - MarketBeat
Parabilis upsizes IPO seeking to raise more than $600M - MSN
PBLS SEC FilingsPARABILIS MEDICINES INC 10-K, 10-Q, 8-K Forms - Stock Titan
Rx Rundown: Incyte, Parabilis Medicines, Pfizer and more - Medical Marketing and Media
PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
PBLS: Static price chart | Parabilis Medicines, Inc. | US6989551014 - marketscreener.com
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock? - Yahoo Finance
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock? - The Motley Fool
Regeneron backed Parabilis seeks up to $476M in US IPO - MSN
Parabilis Medicines (PBLS) 10K Form and Latest SEC Filings 2026 - MarketBeat
Parabilis Medicines, Inc. (PBLS) Stock Price Today & Analysis - Gotrade
Parabilis (NASDAQ: PBLS) reports RA Capital-linked grant of 20,215 stock options - Stock Titan
Parabilis Medicines (PBLS) director receives 20,215 stock options at $20 strike - Stock Titan
Parabilis (PBLS) awards director 20,215 options at $20 strike - Stock Titan
Parabilis (PBLS) director granted 20,215 stock options at $20 strike - Stock Titan
PBLS Price History for Parabilis Medicines Stock - Barchart.com
Parabilis Medicines (PBLS) director receives stock options for 20,215 shares at $20 - Stock Titan
[Form 4] Parabilis Medicines, Inc. Insider Trading Activity - Stock Titan
Parabilis Medicines closes $770.5m IPO, Regeneron investment By Investing.com - Investing.com
Parabilis Medicines closes $770.5 million IPO and concurrent private placement - Investing.com Canada
Parabilis Medicines Raises About $75 Million in Private Placement With Regeneron at 90% of IPO Price - TradingView
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Regeneron backs Parabilis (PBLS) with IPO private placement and new charter - Stock Titan
Is biotech back? Kardigan tries on a $373 million IPO following Parabilis' success - The Business Journals
Parabilis Medicines Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Moomoo
Parabilis Medicines Inc. (PBLS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Parabilis Medicines, Inc.Common Stock (Nasdaq:PBLS) Stock Quote - The Chronicle-Journal
Parabilis Medicines Rings the Closing Bell - Nasdaq
How to Play PBLS Stock After the Parabilis IPO - Barchart.com
Parabilis Is Now the Largest VC-Backed Biotech IPO - Morningstar
Parabilis Reaches $3.7 Billion Market Cap on Frist Day Listed on NASDAQ - Pharmaceutical Executive
HBM Healthcare Investments benefits from successful IPO of Parabilis Medicines - TradingView
Parabilis Medicines, Inc. (PBLS): IPO Prices Above Range, Opens with Massive First-Day Pop - Smartkarma
Parabilis Medicines Shares Rocket Following Record Biotech IPO - WSJ
Parabilis Medicines’ Quest to Drug the Undruggable Picks Up $745M From Upsized IPO - MedCity News
Parabilis now the largest VC-backed biotech IPO - Yahoo Finance
Market Today: GM Expands Battery Business, Parabilis Medicines P - GuruFocus
Parabilis Medicines Inc Stock (PBLS) Financials Data
There is no financial data for Parabilis Medicines Inc (PBLS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Parabilis Medicines Inc Stock (PBLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SEBULSKY ALAN | Director |
Jun 11 '26 |
Buy |
20.00 |
12,500 |
250,000 |
12,500 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):